Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up - Top-Institutions - MDSpire

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

  • By

  • Eva Domingo-Domènech

  • Barbara Pro

  • Tim Illidge

  • Steven Horwitz

  • Lorenz Trumper

  • Swami Iyer

  • Ranjana Advani

  • Nancy L. Bartlett

  • Jacob Haaber Christensen

  • Won-Seog Kim

  • Tatyana Feldman

  • Ilseung Choi

  • Giuseppe Gritti

  • David Belada

  • Andrei Shustov

  • Arpad Illes

  • Pier Luigi Zinzani

  • Andreas Hüttmann

  • Marek Trneny

  • Steven Le Gouill

  • Deepa Jagadeesh

  • Jonathan W. Friedberg

  • Meredith Little

  • Cassie Dong

  • Michelle Fanale

  • Keenan Fenton

  • Kerry J. Savage

  • January 28, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Lymphoma

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Lymphoma

  • #3

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    Washington University School of Medicine (Siteman Cancer Center)
    Washington University School of Medicine (Siteman Cancer Center)

    St. Louis, MO

    Key Differentiators

    • Hematology
    • Oncology
    • Lymphoma

  • #5

    Northwestern University Feinberg School of Medicine
    Northwestern University Feinberg School of Medicine

    Chicago, IL

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

  • by Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage

  • January 28, 2026

Related Content

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas

When Adnexal Lymphoma Mimics Retinal Disease